NCT05049850View on ClinicalTrials.gov

A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 16, 2022

Primary Completion Date

February 5, 2024

Study Completion Date

May 8, 2024

Conditions
Kidney Transplantation in Highly Sensitized Patients
Interventions
DRUG

Imlifidase

Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly specific for IgG.

Trial Locations (1)

10016

NYU Langone Health Transplant Institute, New York

Sponsors

Lead Sponsor

Hansa Biopharma AB
All Listed Sponsors
lead

Hansa Biopharma AB

INDUSTRY

NCT05049850 - A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation | Biotech Hunter | Biotech Hunter